Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters








Database
Language
Publication year range
1.
ACS Infect Dis ; 10(9): 3358-3367, 2024 Sep 13.
Article in English | MEDLINE | ID: mdl-39143042

ABSTRACT

Toward repositioning the antitubercular clinical candidate SQ109 as an antimalarial, analogs were investigated for structure-activity relationships for activity against asexual blood stages of the human malaria parasite Plasmodium falciparum pathogenic forms, as well as transmissible, sexual stage gametocytes. We show that equipotent activity (IC50) in the 100-300 nM range could be attained for both asexual and sexual stages, with the activity of most compounds retained against a multidrug-resistant strain. The multistage activity profile relies on high lipophilicity ascribed to the adamantane headgroup, and antiplasmodial activity is critically dependent on the diamine linker. Frontrunner compounds showed conserved activity against genetically diverse southern African clinical isolates. We additionally validated that this series could block transmission to mosquitoes, marking these compounds as novel chemotypes with multistage antiplasmodial activity.


Subject(s)
Adamantane , Antimalarials , Antitubercular Agents , Plasmodium falciparum , Plasmodium falciparum/drug effects , Antimalarials/pharmacology , Antimalarials/chemistry , Humans , Structure-Activity Relationship , Antitubercular Agents/pharmacology , Antitubercular Agents/chemistry , Adamantane/pharmacology , Adamantane/chemistry , Adamantane/analogs & derivatives , Animals , Malaria, Falciparum/drug therapy , Malaria, Falciparum/parasitology , Inhibitory Concentration 50 , Ethylenediamines
2.
J Med Chem ; 66(11): 7553-7569, 2023 06 08.
Article in English | MEDLINE | ID: mdl-37235809

ABSTRACT

We tested a series of SQ109 analogues against Mycobacterium tuberculosis and M. smegmatis, in addition to determining their uncoupling activity. We then investigated potential protein targets, involved in quinone and cell wall biosynthesis, using "rescue" experiments. There was little effect of menaquinone on growth inhibition by SQ109, but there were large increases in the IC50 of SQ109 and its analogues (up to 20×) on addition of undecaprenyl phosphate (Up), a homologue of the mycobacterial decaprenyl (C50) diphosphate. Inhibition of an undecaprenyl diphosphate phosphatase, an ortholog of the mycobacterial phosphatase, correlated with cell growth inhibition, and we found that M. smegmatis cell growth inhibition could be well predicted by using uncoupler and Up-rescue results. We also investigated whether SQ109 was metabolized inside Mycobacterium tuberculosis, finding only a single metabolite, previously shown to be inactive. The results are of general interest since they help explain the mechanism of SQ109 in mycobacteria.


Subject(s)
Mycobacterium tuberculosis , Tuberculosis , Humans , Antitubercular Agents/pharmacology , Antitubercular Agents/metabolism , Diphosphates/pharmacology , Tuberculosis/drug therapy , Tuberculosis/microbiology , Mycobacterium smegmatis
SELECTION OF CITATIONS
SEARCH DETAIL